ClinicalTrials.gg
Active, not recruitingNCT06813911ADD-VANTAGEUpdated Oct 14, 2026

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

A Phase 3 interventional study of Pelacarsen and Placebo in Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 94 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Now Active, not recruitingEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.

Enrollment
11th of 16
246 · median 401
Started
2025
with 1 other
Phase 3
8 of 16
1 open now
Registered
15th of 16
by date
Lead sponsor
9 of 16
Novartis Pharmaceuticals

Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 11th largest by enrollment, is one of 2 that started in 2025, is one of 8 in phase 3, and was the 15th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inclisiran in Atherosclerosis, or all of them as a file.
02

Study summary

The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study followed by an open-label treatment period.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease (ASCVD)

Keywords

  • Lipoprotein(a)
  • cardiovascular disease
  • ASCVD
  • pelacarsen (TQJ230)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Male and female participants 18 to ≤80 years of age at Screening visit
  • Established ASCVD, defined as documented coronary heart disease (CHD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD) at Screening visit
  • On stable dose of local guideline recommended lipid lowering therapy for at least 30 days prior to Screening visit
  • Participants must successfully complete the run-in period of background inclisiran treatment in order to be randomized
  • On standard of care (SoC) treatment for other CVD risk factors including hypertension and diabetes for at least 30 days prior to Randomization/Baseline visit
  • Central laboratory reported Lp(a) ≥175 nmol/L at Screening visit
  • Central laboratory reported LDL-C >70 mg/dL (or >1.8 mmol/L) at Screening visit

Key Exclusion Criteria:

  • Prior treatment with inclisiran
  • Any other PCSK9 inhibitor (e.g., evolocumab, alirocumab) use within 4 months prior to Screening visit
  • Uncontrolled hypertension at Randomization/Baseline visit
  • Heart failure (NYHA) class IV at Screening visit or at Randomization/Baseline visit (Day 1)
  • Triglycerides ≥400 mg/dL at Screening visit
  • History of of any organ system within the past 5 years
  • Myocardial infarction, stroke or other major bleeding, coronary or lower limb re vascularization, major cardiac or non-cardiac surgery between Screening visit and Randomization/Baseline visit (Day 1)
  • Central laboratory reported count \<140,000 per mm3
  • Active liver disease or hepatic dysfunction at Screening visit
  • Significant kidney disease at Screening visit
  • Pregnant or nursing women at Screening visit
  • Any uncontrolled chronic or serious medical condition which may pose an immediate risk to clinical stability of the study participant at Screening visit

    • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
246 participants (actual)

Study arms

  • Active comparator
    Pelacarsen

    Participants randomized in Pelacarsen arm, will be administered pelacarsen (TQJ230) subcutaneous injection once monthly for 12 months.

    Drug: Pelacarsen · Drug: Inclisiran

  • Placebo comparator
    Placebo

    Participants will be administered placebo subcutaneous injection once monthly for 6 months. After Month 6, all participants will receive pelacarsen 80 mg injection for the remaining 6 months during the open-label treatment period.

    Drug: Pelacarsen · Drug: Placebo · Drug: Inclisiran

Interventions

  • Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.

    Also known as: TQJ230

  • DrugPlacebo

    Placebo will be provided as solution for injection in prefilled syringe for subcutaneous injection.

  • All participants will be administered two loading doses of inclisiran as background treatment at Run-in 1 and Run-in 2, separated by 3 months, according to the approved label. After that inclisiran will be administered every 6 months, i.e., Month 5 and Month 11.

06

What researchers measure

Primary outcomes

  1. Change in log transformed lipoprotein A (Lp(a)) concentration

    To evaluate the efficacy of Pelacarsen compared to placebo, in reducing Lp(a) levels at Month 6 in ASCVD participants who have elevated Lp(a), and who are on background inclisiran for elevated LDL-C

    Time frame: Baseline, 6 Months

Secondary outcomes

  1. Proportion of participants achieving reduction in Lp(a) levels at Month 6

    Efficacy of pelacarsen versus placebo in reducing Lp(a)

    Time frame: Baseline, Month 6

  2. Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

    The TEAEs will be defined as any recorded AE with start date located in the on-treatment period. To understand the effect of pelacarsen versus placebo on safety and tolerability in participants treated with background inclisiran. Incidence and severity of AEs by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs.

    Time frame: 16 Months

  3. Incidence of treatment emergent adverse events of special interest (AESI)

    To understand the effect of pelacarsen versus placebo on safety and tolerability in participants treated with background inclisiran

    Time frame: 12 Months

  4. Incidence of study and treatment discontinuations due to TEAEs

    Incidence proportion of study discontinuations due to TEAEs

    Time frame: 12 Months

07

Study locations

94 sites
  • Parkway Medical Center
    Birmingham, Alabama 35215, United States
  • Clinical Research Inst of Arizona
    Sun City West, Arizona 85375, United States
  • National Heart Institute
    Beverly Hills, California 90211, United States
  • Interv Cardiology Med Grp
    West Hills, California 91307, United States
  • Excel Medical Clinical Trials LLC
    Boca Raton, Florida 33434, United States
  • Jacksonville Center for Clinical
    Jacksonville, Florida 32216, United States
  • K2 Medical Research LLC
    Maitland, Florida 32751, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Baptist Health South
    Miami, Florida 33173, United States
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
  • FXM Clin Res Miramar LLC
    Miramar, Florida 33027, United States
  • Ocala Cardiovascular Research
    Ocala, Florida 34471, United States
  • SEC Clinical Research
    Pensacola, Florida 32503, United States
  • Peace River Cardiovascular Center
    Port Charlotte, Florida 33952, United States
  • University Of South Florida
    Tampa, Florida 33612, United States
  • FC Site Partners Miami
    Winter Park, Florida 32789, United States
  • Advocate Lutheran General Childrens Hospital
    Park Ridge, Illinois 60068, United States
  • American Health Network Research Dept
    Muncie, Indiana 47304, United States
  • Cardiovascular Associates Research
    Covington, Louisiana 70433, United States
  • Omega Clinical Research
    Metairie, Louisiana 70006, United States
  • Flourish Research Bowie
    Bowie, Maryland 20715, United States
  • Anderson Medical Research
    Ft. Washington, Maryland 20744, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • MyMichigan Medical Center Midland
    Midland, Michigan 48670, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Overlook Medical Center
    Summit, New Jersey 07901, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • The Corvallis Clinic P C
    Corvallis, Oregon 97330, United States
  • Novartis Investigative Site
    Tullahoma, Tennessee 37388, United States
  • PharmaTex Research LLC
    Amarillo, Texas 79106, United States
  • Kelsey Seybold Research Foundation
    Houston, Texas 77030, United States
  • Northwest Houston Clinical Research PLLC
    Tomball, Texas 77375, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • Virginia Heart
    Falls Church, Virginia 22042, United States
  • Novartis Investigative Site
    Yinchuan, Ningxia 750004, China
  • Novartis Investigative Site
    Jining, Shandong 272000, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Béziers, 34525, France
  • Novartis Investigative Site
    Cholet, 49325, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Toulouse, 31054, France
  • Novartis Investigative Site
    Stuttgart, Baden-Wurttemberg 70376, Germany
  • Novartis Investigative Site
    Potsdam, Brandenburg 14473, Germany
  • Novartis Investigative Site
    Chemnitz, Saxony 09113, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Bielefeld, 33604, Germany
  • Novartis Investigative Site
    Gelnhausen, 63571, Germany
  • Novartis Investigative Site
    Mannheim, 68165, Germany
  • Novartis Investigative Site
    Münster, 48145, Germany
  • Novartis Investigative Site
    Singen, 78224, Germany
  • Novartis Investigative Site
    Hong Kong, Hong Kong 999077, Hong Kong
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Caserta, CE 81100, Italy
  • Novartis Investigative Site
    Grosseto, GR 58100, Italy
  • Novartis Investigative Site
    Milan, MI 20138, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Perugia, PG 06129, Italy
  • Novartis Investigative Site
    Pordenone, PN 33170, Italy
  • Novartis Investigative Site
    Salerno, SA 84131, Italy
  • Novartis Investigative Site
    Legnago, VR 37045, Italy
  • Novartis Investigative Site
    The Hague, South Holland 2545 AA, Netherlands
  • Novartis Investigative Site
    Enschede, 7512KZ, Netherlands
  • Latin Clinical Trial Center Inc
    San Juan, 00909, Puerto Rico
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Castilleja de la Cuesta, Sevilla 41950, Spain
  • Novartis Investigative Site
    A Coruña, 15006, Spain
  • Novartis Investigative Site
    Barcelona, 08023, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Huelva, 21080, Spain
  • Novartis Investigative Site
    Las Palmas GC, 35010, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Valencia, 46010, Spain
  • Novartis Investigative Site
    Valencia, 46014, Spain
  • Novartis Investigative Site
    Changhua, 50006, Taiwan
  • Novartis Investigative Site
    Kaohsiung City, 80756, Taiwan
  • Novartis Investigative Site
    Tainan, 704, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
  • Novartis Investigative Site
    Chichester, West Sussex PO19 6SE, United Kingdom
  • Novartis Investigative Site
    London, EC1M 6BQ, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Tyne and Wear, NE29 8NH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2028, 33 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 33 months is close to that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 7, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Feb 3, 2028
CompletionEst.
Feb 29, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 7, 2026
Sites
1 site removed
Show 1 removed
  • American Health Network Research Dept · Muncie, United States
Oct 7, 2026
Enrollment
340 (estimated)→246 (actual)
Oct 7, 2026
Show all 2 updates
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 7, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • American Health Network Research Dept · Muncie, United States
    Enrollment 340 (estimated)→246 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06813911
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Apr 30, 2025
Primary completion
Feb 3, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pelacarsen · Inclisiran

Start the discussion